Publicaciones en colaboración con investigadores/as de Hospital General Universitario Gregorio Marañón (29)

2024

  1. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study

    The Lancet Oncology, Vol. 25, Núm. 1, pp. 46-61

  2. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study

    The Lancet Oncology, Vol. 25, Núm. 1, pp. 29-45

2023

  1. Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma

    European Urology Open Science

2022

  1. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

    European Journal of Cancer, Vol. 175, pp. 110-119

  2. Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management

    Critical Reviews in Oncology/Hematology, Vol. 174

2021

  1. Circulating levels of the interferon-γ-regulated chemokines cxcl10/cxcl11, il-6 and hgf predict outcome in metastatic renal cell carcinoma patients treated with antiangiogenic therapy

    Cancers, Vol. 13, Núm. 11

2020

  1. Latest progress in molecular biology and treatment in genitourinary tumours

    Clinical and Translational Oncology, Vol. 22, Núm. 12, pp. 2175-2195

  2. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma

    International Journal of Cancer, Vol. 146, Núm. 5, pp. 1435-1444

2019

  1. Collecting Duct Carcinoma of the Kidney: Analysis of Our Experience at the Spanish 'Grupo Centro' of Genitourinary Tumors

    Kidney Cancer, Vol. 3, Núm. 3, pp. 177-182

  2. Observational Prospective Study to Determine the Evolution of the Symptomatic Profile of Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients and Its Relation to the Control of the Disease

    Advances in Therapy, Vol. 36, Núm. 6, pp. 1497-1508

  3. Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer

    European Journal of Cancer, Vol. 116, pp. 158-168

  4. Real-world outcome of 173 metastatic non-clear cell renal cell carcinoma (nccrcc) cases: The experience of the center group for genitourinary tumors

    Kidney Cancer, Vol. 3, Núm. 1, pp. 41-50

  5. The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)

    Targeted Oncology, Vol. 14, Núm. 1, pp. 15-32

2018

  1. Correction to: Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling (Breast Cancer Research and Treatment, (2018), 171, 3, (627-634), 10.1007/s10549-018-4855-2)

    Breast Cancer Research and Treatment

  2. Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling

    Breast Cancer Research and Treatment, Vol. 171, Núm. 3, pp. 627-634

  3. Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: Toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii286

2017

  1. Docetaxel in prostate cancer: A familiar face as the new standard in a hormone-sensitive setting

    Therapeutic Advances in Medical Oncology, Vol. 9, Núm. 5, pp. 307-318

  2. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial

    The Lancet Oncology, Vol. 18, Núm. 5, pp. 672-681

  3. Recent advances in genitourinary tumors: A review focused on biology and systemic treatment

    Critical Reviews in Oncology/Hematology, Vol. 113, pp. 171-190

2016

  1. Controversies in the treatment of metastatic kidney cancer: A case report and review of the literature

    Cancer and Chemotherapy Reviews, Vol. 11, Núm. 1, pp. 3-11